Briana Costello MD

General & Interventional Cardiologist @Texas_Heart 💉❤️, wife, mother, 👧🏽🐱🐶

[Briana Costello MD @bcostelloMD]

“There is a movement underway, and it has been growing for a long time.”

PROUD to be a part of the movement. #WIC #SheForShe #HeForShe 👩🏼‍⚕️🙌🏼 https://t.co/6EBY4DySSq

[Toniya Singh MD FACC @DrToniyaSingh]

@gina_lundberg @DrLaxmiMehta @biljana_parapid @DrSheilaSahni @bcostelloMD @SamRRazaMD @drbrowncares @rahatheart1 @AnastasiaSMihai @avolgman @DrAnneAlbers @sandylewis @ClaireDuvernoy @DrJMieres @drstaceyrosen @drtaranarula @Pooh_Velagapudi@purna_nalabothu @JelaniAini🙎🏻‍♀️❤️ https://t.co/pYlGRjOzHo

[JACC Journals @JACCJournals]

ACC/AHA & 9 other leading medical associations released an updated clinical guideline for managing #dyslipidemia. About 1 in 4 US adults has high LDL-C, raising risk of heart attack & stroke.

Get the details in #JACC: https://t.co/pT3H1NCzyZ

#ClinicalGuidelines #cvLipids #ASCVD

[Yuri Pride @yuripridemd]

We knew clopidogrel was better a long time ago. And without a higher bleeding risk. Read CAPRIE. Was just really expensive at the time. Now it's my SAPT of choice for most pts when I'm stopping DAPT. Not novel.

[JACC Journals @JACCJournals]

In the large ROLLING STONE registry (1,005 pts, 23 Italian centers) comparing #IVL vs #atherectomy in calcified lesions, procedural success was similar, but IVL showed significantly ⬇️MACE & CV death at 30 days & 12 months. https://t.co/olu95gh1AW #JACCINT @veronica_lio

[Briana Costello MD @bcostelloMD]

@farkomd Nice- but isn’t it Kommerell?

[Harriette Van Spall, MD MPH 🇨🇦 @hvanspall]

In the #Tuxedo2 #RCT of 1800 patients with #T2DM & #MVD in India undergoing #PCI, #ticagrelor not proven non-inferior to #prasugrel on PEP of #MACE
Point estimates favoured prasugrel across endpoints
Non-inferiority margin 5%
Congrats @SripalBangalore & team
#AHA25
@mmamas1973

[Briana Costello MD @bcostelloMD]

@DrMarthaGulati Everything you just said 💯. Now we will spend another few minutes of our already minuscule amount of time with patients trying to undo these non scientific statements.

[Briana Costello MD @bcostelloMD]

@drjohnm This👏🏼👏🏼👏🏼👏🏼👏🏼

[Stephen W. Smith @smithECGBlog]

This is what you get from Trump. Violence against people caring for your children, only because of their color and spanish accent. Witnesses say she has a work permit. Teaches kids spanish at an immersion school.

[John Mandrola, MD @drjohnm]

A very nice study from #EACTS2025. I will cover today on the This Week in Cardiology podcast. Once again, guidelines are too aggressive. And biased toward action.

[Brian Allen @allenanalysis]

🚨 NEW: Netflix secretly recorded an interview with Dr. Jane Goodall in March, set to air only after her death.

In it, she says she wishes Trump and Elon Musk could be blasted into space… and closes with:

“Don’t lose hope.”

Now that’s a final message.

[Richard Ferraro @RichardAFerraro]

My #Cardiology paper of the year: Daily Step Count in @JACCJournals

The optimal steps to ⬇️ CVD events is NOT THAT HIGH! Totally achievable!

Its easy to get discouraged by the marathoners, bodybuilders, etc. Sure that's great, but not necessary. Do enough, the benefits follow

[Kevin Croce MD, PhD @kevinjamescroce]

Agent ISR- YES!! Nearly three-quarters of the patients had intravascular image guided ISR PCI….and the outcomes were very good. Now that’s progress! Let’s next hope for rapid FDA approval of Agent coupled with wide adoption of intravascular imaging for all ISR cases.

[Henry Han @HanCardiomd]

Safety of Continuing #MRA Treatment in Patients with #HFrEF and Severe Kidney Disease

In this study from the Swedish Heart Failure Registry of 33,942 HFrEF patients (EF < 40%):

📍51% received MRA, with varying rates across #eGFR levels.
📍Higher eGFR & severe HF features correlated with more MRA use.
📍MRA use didn't increase risk of renal events, all-cause ☠️, or 🏥 across eGFR levels, including severe #CKD

https://t.co/FdR5K5pNZV @EJHFEiC @HFA_President @MarcoMetra @ESC_Journals

[Thais Coutinho @thaiscoutinhoCV]

🌟Pub alert! While #preeclampsia (PE)⬆️CVD risk, how do we identify those ♀️whose arteries are already on a disease path? Led by @paquin_amelie ,we showed that PE ♀️who remain HTNsive have much worse arterial health, and may be prioritized for #CVPrev ➡️https://t.co/oFGmb69459

[Monika Sanghavi MD, FACC @MonSangh]

Don’t miss this joint AHA/ACC webinar! Achieving gender equity in cardiology requires collaboration with our male allies! Join us to discuss what #HeForShe means in cardiology !

#AHAWIC #ACCWIC @gina_lundberg @PamTaubMD @RBP0612

[Bindu Chebrolu @dr_chebrolu]

📷 "Honored to be in the company of these exceptional #WomenInCardiology. A memorable evening exchanging stories and charting the course for the WIC community's journey ahead. 💙👩‍⚕️ #CardioQueens #HeartbeatsAndHighHeels" 👠🩺#BarbiesinCardiology😍🥰💃#TCACC

[Eric Topol @EricTopol]

Big news #ESC2023 and @NEJM
In a placebo-controlled randomized trial of people with obesity + heart failure (with preserved ejection fraction). semaglutide (Wegovy) markedly improved symptoms, exercise time, reduced inflammatory markers (and weight loss)
https://t.co/3pKdKB7cJH

[JACC Journals @JACCJournals]

#ESCCongress #JACC LBCT SimPub:

New from #DAPA-HF &amp; #DELIVER: Benefit-to-risk ratio may favor continuation of #SGLT2i dapagliflozin in #HeartFailure pts w/ deterioration in kidney function to eGFR&lt;25ml/min/1.73m2 https://t.co/3EF3ILm9fR

@safchat @mvaduganathan @scottsolomon

[NEJM @NEJM]

Late breaking at #ESCCongress: In patients with heart failure with preserved ejection fraction and obesity, semaglutide (2.4 mg) led to greater reductions in symptoms and physical limitations and greater improvements in exercise function than placebo. Full STEP-HFpEF trial:

[Andrew J Sauer MD @AndrewJSauer]

An historic Class 1A recommendation for HFpEF. Expected but still remarkable. #ESCCongress

@escardio

Proud of the many who brought this forward for our patients.

@MkosiborodMD
@MidAmericaHeart
@saintlukeskc